Journal Article

Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial

Posavad, Christine M., Winokur, Patricia L., Makhene, Mamodikoe, Davis, Tamia, Mahgoub, Siham M., Crandon, Sonja, Sherman, Amy C., Atmar, Robert L., Meagher, Megan A., Bäcker, Martín, Malkin, Elissa, Jackson, Lisa A., Walsh, Edward E., Nayak, Seema U., Beigel, John H., Frey, Sharon E., Neuzil, Kathleen M., Giebeig, Lisa A., Martin, Thomas C. S., Kamidani, Satoshi, Anderson, Evan J., Netzl, Antonia, Lyke, Kirsten E., Walsh, Stephen R., Smith, Michael J., El Sahly, Hana M., Roberts, Paul C., Losada, Cecilia, Rouphael, Nadine G., Presti, Rachel M., Samaha, Hady, Luetkemeyer, Anne F., Makowski, Mat, Abate, Getahun, Oikonomopoulou, Zacharoula, Türeli, Sina, Goepfert, Paul A., Novak, Richard M., Telu, Kalyani, Ladner, Benjamin G., Fusco, Dahlene N., Abebe, Kuleni, Baden, Lindsey R., Immergluck, Lilly C., Falsey, Ann R., Eaton, Amanda, Babu, Tara M., Wald, Anna, Stephens, David S., Albert, Jim, Bethony, Jeffrey M., Mu, Jinjian, Dunstan, Maya, Mulligan, Mark J., Porterfield, Laura, Lewis, Teri C., Hill, Heather, Rupp, Richard, Diemert, David J., Graciaa, Daniel S., Wilks, Samuel H., Little, Susan J., Smith, Derek J

2023

Overview

Vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection wanes over time, requiring updated boosters. In a phase 2, open-label, randomized clinical trial with sequentially enrolled stages at 22 US sites, we assessed safety and immunogenicity of a second boost with monovalent or bivalent variant vaccines from mRNA and protein-based platforms targeting wild-type, Beta, Delta and Omicron BA.1 spike antigens. The primary outcome was pseudovirus neutralization titers at 50% inhibitory dilution (ID 50 titers) with 95% confidence intervals against different SARS-CoV-2 strains. The secondary outcome assessed safety by solicited local and systemic adverse events (AEs), unsolicited AEs, serious AEs and AEs of special interest. Boosting with prototype/wild-type vaccines produced numerically lower ID 50 titers than any variant-containing vaccine against all variants. Conversely, boosting with a variant vaccine excluding prototype was not associated with decreased neutralization against D614G. Omicron BA.1 or Beta monovalent vaccines were nearly equivalent to Omicron BA.1 + prototype or Beta + prototype bivalent vaccines for neutralization of Beta, Omicron BA.1 and Omicron BA.4/5, although they were lower for contemporaneous Omicron subvariants. Safety was similar across arms and stages and comparable to previous reports. Our study shows that updated vaccines targeting Beta or Omicron BA.1 provide broadly crossprotective neutralizing antibody responses against diverse SARS-CoV-2 variants without sacrificing immunity to the ancestral strain. ClinicalTrials.gov registration: NCT05289037 . Analysis of antibody responses to COVID-19 vaccines encoding variant-specific spike, with or without ancestral spike, suggests no loss of neutralization of the ancestral virus with variant-only vaccines, which may simplify future vaccine updates.

• Publisher: Nature Publishing Group US,Nature Publishing Group
• Subject: 631/250/590/2293 / 692/308/2779/777 / 692/308/575 / Antibodies / Antigens / Biomedical and Life Sciences / Biomedicine / Broadly Neutralizing Antibodies / Cancer Research / Coronaviruses / COVID-19 / COVID-19 - prevention & control / COVID-19 vaccines / COVID-19 Vaccines - adverse effects / Dilution / Humans / Immunogenicity / Infectious Diseases / Labels / Metabolic Diseases / Molecular Medicine / mRNA / Neurosciences / Neutralization / Prototypes / Safety / SARS-CoV-2 - genetics / Severe acute respiratory syndrome coronavirus 2 / Vaccines / Viral diseases